The Indian Patent Office has rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) application for a patent on the paediatric formulation of World Health Organization (WHO)-recommended TB drug bedaquiline. The MSF welcomed this as a significant step toward increasing affordable access to the lifesaving TB drug for children and urged generic manufacturers to take … Continue reading Indian Patent Office rejects J&J’s application for paediatric formulation of lifesaving TB drug